Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIOngoingD-0291-2025

Drug recall · March 26, 2025

Levothyroxine Sodium Tablets recall

Why: Super-Potent Drug: Out of specification potency results were obtained.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20.

Lots / codes

Lot 3115773, Exp. 03/31/2025

Quantity
1,068 cartons
Company
Mylan Institutional, Inc., Rockford, IL
Distribution
Nationwide in the USA
Initiated
March 7, 2025 · Voluntary: Firm initiated
Classified
March 20, 2025
Reported
March 26, 2025
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Recalled with it (same recall event)

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Levothyroxine

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.